Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology has further expanded its clinical advisory team as it advances towards a first in human clinical trial.

“We are delighted to welcome Dr. Zahid Bashir and Dr Alessandra Cesano to Currus Biologics, where their deep experience leading novel CAR T-cell clinical evaluations will be an asset to the development of the BEAT technology,” commented Sam Cobb, Chief Executive Officer of Currus Biologics. “Dr. Bashir and Dr Cesano bring significant oversight, clinical development, and strategic expertise, having previously guided numerous programs through all phases of development. Their extensive background and experience will be particularly valuable as the Company progresses its lead asset, CUR-001, towards the clinic.”

Dr Bashir added, “Solid tumour cancers are the leading cause of cancer death. CAR T-cells have shown immense benefit in blood cancers, such as leukemia and multiple myeloma, with complete regression rates exceeding 80%, however these cancers represent only 10% of cancer related deaths, leaving a huge unmet need for solid tumours, the remaining 90%. Thus, new approaches are urgently needed for patients with solid tumours such breast, ovarian, lung and colon.”

Dr Alessandra Cesano added “The Currus BEAT and CAR T-cell combination therapy is a potentially transformative treatment and I am excited to be part of the journey to advance the science and understanding of this novel therapy.”

Dr. Zahid Bashir and Dr Alessandra Cesano join clinician researchers Associate Professor Saar Gill and Professor Michael Brown, both at the forefront of CAR T-cell research, development and clinical trial evaluation.